False positive serum biochemical screening and subsequent fetal loss in women less than 35 years of age

British Journal of Obstetrics and Gynaecology

Volumn 108, Issue 6, 2001, Pages 589-593

  Antsaklis, Aris J ^a   Papantoniou, Nikolaos E ^a   Daskalakis, George J ^a   Mesogitis, Spyros A ^a   Kitmirides, Stylianos J ^a   Michalas, Stylianos S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN; ESTRADIOL;

ADULT; ARTICLE; BLOOD; DOWN SYNDROME; FEMALE; FETUS DEATH; HUMAN; LABORATORY DIAGNOSIS; METHODOLOGY; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; STANDARD;

ADULT; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; DOWN SYNDROME; ESTRADIOL; FALSE POSITIVE REACTIONS; FEMALE; FETAL DEATH; HUMANS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES;

EID: 0035374947     PISSN: 03065456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-5456(00)00137-6     Document Type: Article

References (35)

1. Heyl PS, Miller W, Canick JA. Maternal serum screening for aneuploid pregnancies by alpha-fetoprotein, hCG and unconjugated estriol. Obstet Gynecol 1990;76:1025-1031.
2. MacDonald ML, Wagner RM, Slotnick RN. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age. Obstet Gynecol 1991;77:63-68.
3. Haddow JE, Palomaki GE, Knight GJ, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992;327:588-593.
4. Philips OP, Elias S, Shulman LP, Anderson RN, Morgan CD, Simpson JL. Maternal serum screening for fetal Down's syndrome in women less than 35 years of age using alpha-fetoprotein, hCG and unconjugated estriol: a prospective 2-year study. Obstet Gynecol 1992;80:353-358.
5. Spencer K, Carpenter P. Prospective study of prenatal screening for Down's syndrome with free-human chorionic gonadotrophin. BMJ 1993;307:764-769.
6. Burton BK. Outcome of pregnancy in patients with unexplained elevated or low levels of maternal serum alpha-fetoprotein. Obstet Gynecol 1988;72:709-713.
7. Milunski A, Jick SS, Bruell C, et al. Predictive values, relative risks, and overall benefits of high and low maternal serun (α-fetoprotein screening in singleton pregnancies: New epidemiologic data. Am J Obstet Gynecol 1989;161:291-297.
8. Katz UL, Chescheir NC, Cefalo RC. Unexplained elevations of maternal serum AFP. Obstet Gynecol Surv 1990;45:719-726.
9. Waller DK, Lustig LS, Cunningham GC, Golbus MS, Hook EB. Second-trimester maternal serum alpha-fetoprotein levels and the risk of subsequent fetal death. N Engl J Med 1991;325:6-10.
10. Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB. The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, pre-eclampsia, and placental complications. Obstet Gynecol 1996;88:816-822.
11. Conen R, Perz R, David M, Dar H, Merksamer R, Sharf M. The association between unexplained second-trimester maternal hCG elevation and pregnancy complications. Obstet Gynecol 1992;80:83-86.
12. Sorensen TK, Williams MA, Zingheim RW, Clement SJ, Hickok DE. Elevated second-trimester human chorionic gonadotropin and subsequent pregnancy-induced hypertension. Am J Obstet Gynecol 1993;169:834-838.
13. Pergament E, Stein AK, Fiddler M, Cho NH, Kupfermine MJ. Adverse pregnancy outcome after a false positive screen for Downs syndrome using multiple markers. Obstet Gynecol 1995;86:255-258.
14. Kowalczyk TD, Cabaniss ML, Cusmano L. Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstet Gynecol 1998;91:396-400.
15. Moore TR, Piacquadio K. A prospective evaluation of fetal movement screening to reduce the incidence of antepartum fetal death. Am J Obstet Gynecol 1989;160:1075-1080.
16. Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum screening for Down syndrome in early pregnancy. BMJ 1988;297:883-887.
17. Antsaklis A, Papantoniou N, Xygakis A, Mesogitis S, Tzortzis E, Michalas S. Genetic amniocentesis in women 20-34 years old: associated risks. Prenat Diagn 2000;20(3):247-250.
18. Jauniaux E, Gulbis B, Tunkel S, Ramsay B, Campbell S, Meuris S. Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high risk pregnancies. Prenat Diagn 1996;12:1129-1135.
19. Muller F, Savery L, Le Fiblec B, et al. Maternal serum human chorionic gonadotropin level at fifteen weeks is a predictor for pre-eclampsia. Am J Obstet Gynecol 1996;175:37-40.
20. Morssink LP, Heringa MP, Beekhuis JR, De Wolf BTHM, Mantingh A. The association between hypertensive disorders of pregnancy and abnormal second-trimester maternal serum levels of hCG and alpha-fetoprotein. Obstet Gynecol 1997;89:666-670.
21. Walton DL, Norem CT, Schoen EJ, Ray GT, Colby CJ. Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy. N Engl J Med 1999;341:2033-2038.
22. Hsu CD, Chan DW, Iriey B, Johnson TRB, Hong SF, Repke JT. Elevated serum human chorionic gonadotropin as evidence of secretory response in severe preeclampsia. Am J Obstet Gynecol 1994;170:1135-1138.
23. Liepman RE, Williams MA, Ceng EY, et al. An association between elevated levels of human chorionic gonadotropin in the midtrimester and adverse pregnancy outcome. Am J Obstet Gynecol 1993;168:1852-1857.
24. Ashour AMN, Lieberman ES, Wilkins Haug LE, Repke JT. The value of elevated second-trimester-human choriogonadotropin in predicting development of pre-eclampsia. Am J Obstet Gynecol 1997;176:438-442.
25. Bashore RA, Westlake JR. Plasma estriol values in high risk pregnancies. Am J Obstet Gynecol 1977;128:371-380.
26. Distler W, Gabbe SG, Freeman RK, Mestman JH, Goebelsmann U. Unconjugated estriol and total plasma estriol in the management of pregnant diabetic patients. Am J Obstet Gynecol 1978;130:424-431.
27. Simpson JL, Nadler HL. Maternal serum alpha-fetoprotein screening in 1987. Obstet Gynecol 1987;69:134-135.
28. Hsieh TT, Hung TH, Hsu JJ, Shau WY, Su CW, Hsieh FJ. Prediction of adverse perinatal outcome by maternal serum screening for Down syndrome in an asian population. Obstet Gynecol 1997;89:937-940.
29. Berkeley AS, Killackey MA, Cederqvist LL. Elevated maternal serum a-fetoprotein levels associated with breakdown in fetal-maternal-placental barrier. Am J Obstet Gynecol 1983;146:859-861.
30. Katz VL, Bowes WA, Sierkh AE. Maternal floor infarction of the placenta associated with elevated second trimester serum alpha-fetoprotein. Am J Perinatol 1987;4:225-228.
31. Boyd PA. Why might maternal serum alpha-fetoprotein be high in pregnancies in which the fetus is normally formed? Br J Obstet Gynaecol 1992;99:93-95.
32. Dungan JS, Shulman LP, Philips OP, et al. Positive serum screening for fetal Down syndrome does not predict adverse pregnancy outcome in absence of fetal aneuploidy. J Soc Gynecol Invest 1994;1:55-58.
33. Chapman SJ, Brumfield CG, Wenstrom KD, DuBard MB. Pregnancy outcomes following false-positive multiple marker screening tests. Am J Perinatol 1997;14:475-478.
34. Ogle R, Jauniaux E, Pahal GS, Dell E, Sheldrake A, Rodeck C. Serum screening for Downs syndrome and adverse pregnancy outcomes: a case-controlled study. Prenat Diagn 2000;20:96-99.
35. Wolf EA, Turnquest MA. Triple marker screening and pregnancy outcomes: statistical methods and results. Obstet Gynecol 2000;95:43.